Actemra Purple Book BLA 125472
- BLA number
- 125472
- Proprietary names
- Actemra
- Proper names
- tocilizumab
- Applicant
- Genentech, Inc.
- Center
- CDER
- First observed release
- 2020-05-01
- Latest observed release
- 2026-06-01
- Newest archive release
- 2026-06-01
- FDA patent list
- No patents listed in the captured FDA patent list; source updated 2025-06-11
- Coverage
- Present in newest release
Latest Known Product Presentations#
Product, Proprietary name, Proper name table| Product | Proprietary name | Proper name | License type | Strength | Dosage form | Route | Presentation | Marketing | Licensure | Approval | Patent list provided |
|---|
| 001 | Actemra | tocilizumab | 351(a) | 162MG/0.9ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | Licensed | 2013-10-21 | |
| 002 | Actemra | tocilizumab | 351(a) | 162MG/0.9ML | Injection | Subcutaneous | Autoinjector | Rx | Licensed | 2018-11-19 | |
Published Patent List#
No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.
Official Monthly Change Events#
Release, Event, Product table| Release | Event | Product | Name | License type | Status | Applicant |
|---|
| 2024-11-01 | U | 001 | Actemra | 351(a) | Rx | Genentech, Inc. |
| 2024-11-01 | U | 002 | Actemra | 351(a) | Rx | Genentech, Inc. |
| 2021-07-01 | U | 001 | Actemra | 351(a) | Rx | Genentech, Inc. |
| 2021-07-01 | U | 002 | Actemra | 351(a) | Rx | Genentech, Inc. |
| 2020-05-01 | R | 001 | Actemra | 351(a) | Rx | Genentech, Inc. |
| 2020-05-01 | R | 002 | Actemra | 351(a) | Rx | Genentech, Inc. |
Observed Product State History#
Release, Product, Name table| Release | Product | Name | License type | Marketing | Licensure | Approval |
|---|
| 2020-05-01 | 001 | Actemra | 351(a) | Rx | Licensed | 2013-10-21 |
| 2020-05-01 | 002 | Actemra | 351(a) | Rx | Licensed | 2018-11-19 |